Heavily Pretreated Relapsed/Refractory Multiple Myeloma

Analysis of online conversations among health care professionals on social media during August revealed significant support for the first oral treatment for postpartum depression.

The combination of mezigdomide and dexamethasone exhibited activity among patients with heavily pretreated multiple myeloma, according to study results published in The New England Journal of Medicine.

The FDA granted accelerated approval to talquetamab-tgvs for treatment of certain patients with relapsed or refractory multiple myeloma.

Long-term results from the KarMMa trial continued to yield frequent deep and durable responses with idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in heavily pretreated patients with relapsed or refractory multiple myeloma.

Subcutaneous elranatamab demonstrated efficacy and a manageable safety profile in patients with relapsed or refractory multiple myeloma, according to data presented at the virtual ASCO Annual Meeting.

Isatuximab plus pomalidomide and low-dose dexamethasone continued to show significant improvement in time to next treatment and PFS2 compared with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma, according to updated results from the ICARIA-MM study.